Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Search trials by disease or condition

Enter a condition, keyword, or NCT ID

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results matching your filters

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background DapagliflozinRecruiting
NCT07662135Phase 3Updated Aug 4, 2026
Sponsor: AstraZeneca
Type 2 Diabetes Mellitus · Type 2 Diabetes With Chronic Kidney Disease
United States, Bulgaria, China, Denmark, Germany +11 more
A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated CardiomyopathyRecruiting
NCT07210723Phase 2, Phase 3Updated Aug 4, 2026
Sponsor: Kardigan, Inc.
Symptomatic Genetic Dilated Cardiomyopathy
United States, Belgium, Denmark, France, Hungary +6 more
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AMLRecruiting
NCT06652438Phase 3Updated Aug 4, 2026
Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland
Acute Myeloid Leukemia, Adult
United States, Australia, Austria, Belgium, Denmark +13 more
A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)Recruiting
NCT05562947Phase 3Updated Aug 4, 2026
Sponsor: Hoffmann-La Roche
Neovascular Age-related Macular Degeneration · nAMD
China
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR VariantRecruiting
NCT06563895Phase 3Updated Aug 4, 2026
Sponsor: Eidos Therapeutics, a BridgeBio company
Amyloidosis · Amyloid Cardiomyopathy · Transthyretin Amyloidosis · Cardiomyopathies
United States, Argentina, Australia, Belgium, Brazil +19 more
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell TherapyRecruiting
NCT07188558Phase 3Updated Aug 4, 2026
Sponsor: Lyell Immunopharma, Inc.
Large B-cell Lymphoma · Lymphoma, B-Cell · Relapsed Non-Hodgkin Lymphoma · Refractory Non-Hodgkin Lymphoma
United States
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes MellitusRecruiting
NCT07662109Phase 3Updated Aug 4, 2026
Sponsor: AstraZeneca
Type 2 Diabetes Mellitus
United States, Argentina, Brazil, China, Czechia +19 more
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's DiseaseRecruiting
NCT06819891Phase 3Updated Aug 4, 2026
Sponsor: Hoffmann-La Roche
Moderately to Severely Active Crohns Disease
United States, Argentina, Australia, Austria, Belgium +21 more
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet ChemotherapyRecruiting
NCT07225270Phase 3Updated Aug 4, 2026
Sponsor: Genmab
Ovarian Cancer · Platinum-sensitive Ovarian Cancer · PSOC
United States, Japan
Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking SurgeryRecruiting
NCT06476184Phase 3Updated Aug 4, 2026
Sponsor: ARCAGY/ GINECO GROUP
Ovarian Cancer
France, Italy, Japan, Netherlands
A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)Recruiting
NCT07656415Phase 3Updated Aug 4, 2026
Sponsor: Agios Pharmaceuticals, Inc.
Sickle Cell Disease
United States
Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical OutcomesRecruiting
NCT07216235Phase 3Updated Aug 4, 2026
Sponsor: Zydus Therapeutics Inc.
Primary Biliary Cholangitis
United States
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)Recruiting
NCT07684235Phase 3Updated Aug 4, 2026
Sponsor: Amgen
Obesity · Overweight
United States, Australia
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure TherapyRecruiting
NCT07225686Phase 3Updated Aug 4, 2026
Sponsor: Amgen
Obesity · Obstructive Sleep Apnea
United States, Australia, Brazil, Canada, Czechia +6 more
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract CancerRecruiting
NCT04628767Phase 2, Phase 3Updated Aug 4, 2026
Sponsor: National Cancer Institute (NCI)
Renal Pelvis and Ureter Urothelial Carcinoma
United States
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast CancerRecruiting
NCT07173751Phase 3Updated Aug 3, 2026
Sponsor: BioNTech SE
Breast Neoplasms
United States, Australia, Belgium, Brazil, China +9 more
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsRecruiting
NCT07185997Phase 3Updated Aug 3, 2026
Sponsor: ArriVent BioPharma, Inc.
Non-Small-Cell Lung Cancer · Metastatic Non-Small-Cell Lung Cancer · Advanced Non-Small-Cell Lung Cancer · EGFR P-Loop and Alpha C-Helix Compressing
United States, Australia, Canada, France, Greece +11 more
A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and SafetyRecruiting
NCT07019922Phase 3Updated Aug 3, 2026
Sponsor: Praxis Precision Medicines
Epileptic Encephalopathy · SCN2A Encephalopathy
United States, Brazil, Germany, Italy
NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)Recruiting
NCT06081244Phase 3Updated Aug 3, 2026
Sponsor: Women's Cancer Study Group GmbH
Triple Negative Breast Cancer
Germany
Effects of Butylphthalide Enhanced With Tenecteplase on Neurological Function in Mild Disabling Acute Ischemic StrokeRecruiting
NCT07369999Phase 3Updated Aug 3, 2026
Sponsor: Xiangya Hospital of Central South University
Mild Disabling Acute Ischemic Stroke
China
Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic ArthritisRecruiting
NCT06654882Phase 3Updated Aug 3, 2026
Sponsor: Duke University
Polyarticular Course Juvenile Idiopathic Arthritis (JIA)
United States, Germany, Italy
A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic PouchitisRecruiting
NCT06443502Phase 3Updated Aug 3, 2026
Sponsor: Takeda
Pouchitis
Belgium, Croatia, Czechia, Greece, Israel +3 more
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung CancerRecruiting
NCT06868277Phase 3Updated Aug 3, 2026
Sponsor: AstraZeneca
Carcinoma, Non-Small Cell Lung
United States, Argentina, Australia, Belgium, Brazil +22 more
Multicenter Clinical Trial of ST-02 for Ablation of Upper Tract Urothelial CarcinomaRecruiting
NCT06124976Phase 2, Phase 3Updated Aug 3, 2026
Sponsor: Peter Black
Urothelial Carcinoma of the Renal Pelvis and Ureter · Transitional Cell Cancer of the Renal Pelvis and Ureter
Canada
Intensification of Blood Pressure Lowering Therapeutics Based on Diuretics Versus Usual Management for Uncontrolled Hypertension IN Patients With Moderate to Severe Chronic Kidney DiseaseRecruiting
NCT05732727Phase 3Updated Aug 3, 2026
Sponsor: University Hospital, Tours
Chronic Kidney Disease(CKD) · Uncontrolled Hypertension
France

Previous page Next page